Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
about
Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study.Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in SingaporeG-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy.The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised conA cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer.Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML).Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cCosts associated with febrile neutropenia in the US.Unplanned presentations of cancer outpatients: a retrospective cohort study.Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment.Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore.Incidence-based cost-of-illness model for metastatic breast cancer in the United States.The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA."Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.
P2860
Q34580490-259C2A98-6D6E-4560-B1D6-C09E49FC0886Q34677539-0955367B-CFC9-45D1-9C9A-3740ADF8D01FQ34982532-7C87AA96-A75F-4A12-BFA8-35158B6E4411Q35006851-46FDEE4A-C1A4-42DD-91F6-2A034166F341Q35532487-7D877BD9-CC7A-479F-BDAA-085D619291B0Q36095199-9A8097A1-809B-4C3F-A443-AA052DE4F3A2Q36197971-8C4264EE-8DED-4279-B70E-A00059077371Q37072515-C42E52F7-7E82-466B-A289-547445729531Q37363328-87816AC4-B27C-4DB6-9FF3-62AD29C8EBC2Q38152967-51217154-6922-4631-8597-1BAFF9928DF9Q38225700-43EB68E6-2320-4A6B-A162-2EB5E6C00750Q40223613-18786719-E545-40DC-9ACC-7A7A4DACC887Q40274712-2ABC895B-3569-42E3-96E8-D432133516F7Q40280346-975F4C55-72FE-4734-9A0D-D9003422CA2EQ40282702-8E10C882-31E8-46F2-B867-5CBCB181D72FQ40284053-E17E76E1-7A49-409D-B7F1-78DE13E1738AQ40324761-5AD790BB-C589-4498-AE85-EDAE1015E8E1Q40348250-5B1E216B-633C-4D03-83B8-3978F4F74337Q44198943-4EDA1DC2-2F5A-4DE9-B5F4-9170C012FDD1Q44244967-63DB9C2C-7227-4D1B-9B7C-4DEDBF37E6D5Q44711105-FA00DF05-1E12-4F67-B3AC-D392D06871CFQ47551703-E74089A2-BCAF-4337-A3AC-5ECFD88F883BQ53161630-E2C7B8D4-C8A6-4E0C-B686-1DF798A8A2E5
P2860
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Evaluating the total costs of ...... nity oncology cancer patients.
@en
Evaluating the total costs of ...... nity oncology cancer patients.
@nl
type
label
Evaluating the total costs of ...... nity oncology cancer patients.
@en
Evaluating the total costs of ...... nity oncology cancer patients.
@nl
prefLabel
Evaluating the total costs of ...... nity oncology cancer patients.
@en
Evaluating the total costs of ...... nity oncology cancer patients.
@nl
P921
P1433
P1476
Evaluating the total costs of ...... nity oncology cancer patients.
@en
P2093
Charles L Bennett
Elizabeth A Calhoun
P304
P356
10.1634/THEONCOLOGIST.12-4-478
P577
2007-04-01T00:00:00Z